Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Preclinical efficacy of first-in-class TCB antibody EM-801

Dec. 14, 2015

First patient dosed in phase I/II study of NKTR-214

Dec. 11, 2015

ISA-101 assessed in phase II combination trial with checkpoint inhibitor nivolumab

Dec. 10, 2015

IL-15N72D/IL-15Ralpha-Fc superagonist complex shows promise for high-risk hematologic malignancies

Dec. 9, 2015

Amgen and Merck & Co. form cancer immunotherapy collaboration

Dec. 9, 2015

Morphotek and University of Wisconsin-Madison to study farletuzumab

Dec. 7, 2015

Novel ADCs have a significant cytotoxic effect both in vitro and in vivo

Dec. 4, 2015

Lilly's Portrazza available as first-line therapy for metastatic squamous NSCLC

Dec. 4, 2015

Phase II dose determined for tremelimumab plus gefitinib in EGFR-mutant NSCLC

Dec. 4, 2015

Anti-survivin vaccine induces immune response in phase II trial in DLBCL

Dec. 3, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...